Immobilization-induced severe hypercalcaemia successfully treated with reduced dose of zoledronate in a maintenance haemodialysis patient

Nephrology (Carlton). 2018 Oct;23(10):963-964. doi: 10.1111/nep.13246.

Authors

Shunsuke Yamada^{1

2}, Hokuto Arase^{1

2}, Sayaka Tachibana^{1

2}, Keigo Tomita^{1

2}, Masahiro Eriguchi^{1

2}, Kiichiro Fujisaki^{1

2}, Yasuhiro Okabe³, Masafumi Nakamura³, Toshiaki Nakano^{1

4}, Kazuhiko Tsuruya¹, Takanari Kitazono¹

Affiliations

¹ Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
² Division of Kidney Care Unit, Kyushu University Hospital, Fukuoka, Japan.
³ Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
⁴ Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

PMID: 30251313
DOI: 10.1111/nep.13246

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Bed Rest / adverse effects*
Bedridden Persons*
Biomarkers / blood
Bone Density Conservation Agents / administration & dosage*
Calcium / blood*
Humans
Hypercalcemia / blood
Hypercalcemia / diagnosis
Hypercalcemia / drug therapy*
Hypercalcemia / etiology
Male
Renal Dialysis*
Severity of Illness Index
Treatment Outcome
Up-Regulation
Zoledronic Acid / administration & dosage*

Substances

Biomarkers
Bone Density Conservation Agents
Zoledronic Acid
Calcium